product pipeline

T3 Implant

for the treatment of Hypothyroidism

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market

The T3 implant is a subdermal implant utilizing Titan's proprietary ProNeura drug delivery platform. It has the potential to offer continuous delivery of T3 for patients who need it in their hypothyroidism treatment regimen.

Overview of T3 Implant

Hypothyroidism is a disease affecting about 15 million Americans, most of whom are women. Symptoms include chronic fatigue, weight gain and obesity, dry skin, impaired mental activity, and depression. The majority of patients are diagnosed using standard blood tests and receive treatment typically consisting of synthetic prohormone thyroxine (T4) given as a once-daily oral medication (Synthroid®, Levoxyl®, generics), which in turn is converted in the body to the active T3. Based upon symptoms and blood tests it is estimated that as many as 15-20 percent of hypothyroid patients are not adequately treated with this therapy, resulting in a persistent deficiency in the primary active form of thyroid hormone, T3, and physicians typically add an oral T3 regimen to the treatment of these patients.

Once-daily synthetic T3 (Cytomel®) is an effective medication for hypothyroidism but can come with potential side effects such as headache, nervousness, irritability, sweating, and cardiac arrhythmias, which are caused by the peak-and-trough blood-level fluctuations of T3 associated with standard oral delivery. An implantable T3 product utilizing the ProNeura drug delivery platform that more closely replicates normal thyroid physiology and avoids the potential side effects associated with the fluctuating drug level in the blood from the oral formulation could benefit patients and fulfill a great, unmet medical need.

The ProNeura Long-term, Continuous Drug Delivery Platform

ProNeura is designed to provide continuous drug release with non-fluctuating medication levels over a period of three months to a year. It is ideal for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration.

Learn More About ProNeura